Search results
Results from the WOW.Com Content Network
Drug companies face inflation penalty. List prices on 20 of the drugs increased faster than the rate of inflation. Under the 2022 federal law, drugmakers must pay rebates to Medicare if list ...
The Medicare drug price negotiation program — that allows the federal health insurance program for people age 65 or older to negotiate the price of certain drugs with the companies that make ...
Prescription drug list prices in the United States continually are among the highest in the world. [1] [2] The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015.
Starting Jan. 1, millions of Americans who get their prescription drugs through Medicare could get a major financial break when a $2,000 out-of-pocket spending cap on medications goes into effect.
In January 2007, the 110th United States House of Representatives approved H.R. 4, the Medicare Prescription Drug Price Negotiation Act, [1] a bill to require federal officials to negotiate with drug companies for lower prices for the 23 million senior citizens who have signed up for Medicare's prescription drug coverage.
The 15 drugs accounted for $41 billion, or 14%, of total Medicare Part D spending between Nov. 1, 2023, and Oct. 1, 2024.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The 15 drugs on the list were used by about 5.3 million Medicare enrollees and treat a variety of diseases, including asthma, cancer and diabetes. The negotiated prices won’t take effect until 2027.